ALRN

Aileron Therapeutics, Inc.

3.20 USD
+0.11 (+3.56%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aileron Therapeutics, Inc. stock is down -1.54% since 30 days ago. The next earnings date is Aug 9, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 7 July’s closed higher than June.

About Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. Company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma.